Chiesi Ventures
Overview
Chiesi Ventures is a venture capital firm focused on the area of rare and orphan disorders. Its goal is to complement the strategic interest of the Chiesi Group by investing in early stage development opportunities. Chiesi Ventures also aims to accelerate the expansion of the Chiesi network in the EU and the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| CuraSen Therapeutics, Inc. | Nov 2021 | Series A Extension | Co-investor |
| Sentien Biotechnologies | Apr 2017 | Series A | Co-investor |
| Glycomine | Apr 2025 | Series C | - |
| Minoryx Therapeutics | May 2022 | Series C | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Chiesi Ventures based?
Chiesi Ventures is headquartered in Boston, Massachusetts, United States.
When was Chiesi Ventures founded?
Chiesi Ventures was founded in 2014.
How many portfolio companies does Chiesi Ventures have?
Chiesi Ventures has 4 portfolio companies in Caplight's dataset.
What are some companies in Chiesi Ventures's portfolio?
Portfolio companies visible on Caplight include CuraSen Therapeutics, Inc., Sentien Biotechnologies, Glycomine, Minoryx Therapeutics.
What was Chiesi Ventures's most recent investment shown here?
Chiesi Ventures's most recent investment in this portfolio sample was in Glycomine in 2025.
What sectors does Chiesi Ventures focus on?
Chiesi Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Chiesi Ventures focus on?
Chiesi Ventures typically invests at the Mid stage.
What is Chiesi Ventures's AUM?
Chiesi Ventures's assets under management are estimated between $50.0M and $100.0M.